When it comes to CRISPR, our society has some important decisions to make.
Just last week, scientists reported a new first in the journal Nature: They edited heritable cells in human embryos to treat an inherited form of heart disease. The day after the research was published, a group of genetics experts published a statement calling for further debate before applications of the technology are taken any further in humans.
According to a new survey of 1,600 adults published in the journal Science today, much of the American public shares this desire for engagement in decision-making. Led by Dietram Scheufele, a professor of science communication at the University of Wisconsin – Madison, the study found that while support for gene editing applications varies, a majority of respondents think the public should be consulted before genome editing is used in humans.
Gene editing presents the potential for remarkable benefits.
The potential to cure genetic disease and to ensure the safety of the world’s food supply in the face of climate change are perhaps the most exciting opportunities, said Jennifer Doudna, a chemist at UC Berkeley who was an early pioneer of the powerful gene-editing technique CRISPR-Cas9 and was not involved in the new study.
But it also raises some serious ethical questions, especially when we turn our attention to tweaking the human genome, Scheufele said. Many people find some applications like disease treatment valuable, and others like making your children more intelligent morally shaky.
For example, scientists may eventually develop a cure for what some people dont consider an illness like a disability, Scheufele said. Would those who chose not to undergo genetic therapy or who couldnt afford it then be discriminated against even more as a result?
These and other ethical concerns go beyond the bounds of science, Scheufele says, and his poll results show that the public wants to be involved in the debate.
Oregon Health & Science University
Embryos develop into blastocysts after co-injection, which could someday be used in fertility clinics to help people trying to have children free of genetic disease.
Embryos develop into blastocysts after co-injection, which could someday be used in fertility clinics to help people trying to have children free of genetic disease. (Oregon Health & Science University)
Because of the fast-moving progress of gene editing research and the vast potential for both beneficial applications and negative consequences, many experts have called for public engagement on the issue including in a consensus report released this year by the National Academy of Sciences (NAS) and the National Academy of Medicine (NAM).
The new study strove to answer some questions emerging from the National Academies report. First, how do people feel about different applications of gene editing? And secondly, do Americans agree that the public should be consulted on gene editing applications? Similar questions had been asked in previous polls, but the authors wanted to get some more specific data.
Human genome editing can be used for two broad purposes: therapy or enhancement. Therapeutic applications include the treatment of genetic disorders like muscular dystrophy or sickle cell disease, while enhancement might be used to change your daughters eye color or make her grow taller.
Each of these changes can be heritable or not, depending on which type of cell is tweaked. Somatic cells are nonreproductive, so any changes to these cells will not be passed on to future generations. Germline cells, on the other hand, are heritable therefore, any modifications will be inherited by the treated persons children and grandchildren.
Reprinted with permission from D.A. Scheufele et al., Science 357:6351 2017
A graphic from the paper showing the acceptance of gene editing by application.
A graphic from the paper showing the acceptance of gene editing by application. (Reprinted with permission from D.A. Scheufele et al., Science 357:6351 2017)
The new poll shows that two-thirds of Americans support therapeutic applications, whether to somatic (64% support) or germline (65% support) cells. When it comes to enhancement, however, there is much less approval. Only 39% of respondents find somatic enhancement acceptable, with 35% saying it is unacceptable. Levels of support dropped even lower for heritable germline enhancement, to 26% in acceptance and 51% in opposition.
When these results were broken down by how religious respondents were, some variation emerged. Religious people are less supportive of genome editing overall. Only half of them expressed some support of treatment applications, compared with 75% of nonreligious respondents. When it comes to enhancement, 28% of religious respondents and 45% of nonreligious people reported some level of support.
The authors also ranked respondents in terms of low, medium and high knowledge by their score on a nine-question factual quiz. Those in the high-knowledge category were far more supportive of treatment applications, with 76% in support compared with only 32% of low-knowledge respondents.
When asked about enhancement applications, the high-knowledge group was very polarized, with 41% in support and a nearly equal amount in opposition. In contrast, half of low-knowledge people reported that they neither support nor oppose gene editing.
Robert Blendon, who studies health policy at the Harvard School of Public Health, said that the polarization could be there for a reason. Those who know more about the technology have probably learned about it because they have a vested interest maybe a genetic disease runs in their family or they are concerned with ethical consequences.
Reprinted with permission from D.A. Scheufele et al., Science 357:6351 2017
A graphic from the paper showing the opinions of respondents based on religiosity and knowledge.
A graphic from the paper showing the opinions of respondents based on religiosity and knowledge. (Reprinted with permission from D.A. Scheufele et al., Science 357:6351 2017)
The more religious people were, the less likely they were to trust the scientific community to responsibly develop new technologies. This trend was opposite when it came to knowledge: The more knowledgeable people were about the technology, the more likely they were to trust the scientists.
While the two groups may have very different reasons, both highly religious and highly knowledgeable people agreed that the public should be involved in decision-making before gene editing is used in humans.
Blendon said that while its clear the public wants a say in how gene editing is used, its unclear exactly what public engagement looks like. The first way most people might think of being consulted is through their elected officials, but other surveys suggest that the public actually doesnt think the government should be making decisions about genome technology.
Scheufele said that there is currently no infrastructure in place for crucial two-way communication between scientists and the public on the genome editing issue but its important to develop it.
Diverse groups and perspectives have an important role to play in shaping the early stages of human genome editing research, Scheufele said. Scientists may not think to investigate all the questions that the public may deem vital.
If we ask the wrong questions, he said, then we may have perfect technical answers to all the wrong questions.
- Early movers: XOM, SRPT, NAV, HDS, NWL, TRVG, GIII, HPE & more - CNBC - September 6th, 2017
- Shares of Sarepta Therapeutics soar on positive drug study results - CNBC - September 6th, 2017
- Mid-Afternoon Market Update: Crude Oil Up Over 1%; Sarepta Shares Jump After Positive Results In DMD Treatment ... - Benzinga - September 6th, 2017
- Gene Therapy for OPMD Nears Human Studies, Benitec Announces - Muscular Dystrophy News - September 6th, 2017
- Jerry Lewis' work pays off in new drugs for muscular dystrophy ... - Allentown Morning Call - September 5th, 2017
- Lynchburg firefighters have boots on the ground to fill the boot for muscular dystrophy - Lynchburg News and Advance - September 5th, 2017
- Europe Limb-Girdle Muscular Dystrophy Market and Competitive Landscape 2017-2021 - Research and Markets - Business Wire (press release) - September 5th, 2017
- Summit Announces Positive Top-Line Data From an Exploratory Phase 2 Clinical Trial Supporting Ridinilazole as a ... - GlobeNewswire (press release) - September 5th, 2017
- Investigating the genetics behind muscular dystrophy in dogs - BMC Blogs Network (blog) - September 5th, 2017
- Mom Starts Fund to Find Cure for Duchenne Muscular Dystrophy ... - PEOPLE.com - September 2nd, 2017
- Firefighters taking part in 'Fill the Boot' campaign - Finger Lakes Times - September 2nd, 2017
- Chemical Differences Made One Duchenne Therapy, Exondys 51, Succeed and Another Fail - Muscular Dystrophy News - September 2nd, 2017
- Family seeks funds to treat teenager with genetic disorder - The Star Online - September 2nd, 2017
- Lynchburg fire captain spearheads calendar featuring ladies of the LFD - Lynchburg News and Advance - August 29th, 2017
- A fitting tribute to a fundraising giant - Fort Wayne Journal Gazette - August 23rd, 2017
- Once Again, Muscular Dystrophy Patients Say, 'Not in My Name!' - PETA (blog) - August 23rd, 2017
- Godfrey firefighters, Shivers team up against muscular dystrophy - AdVantage News - August 23rd, 2017
- Why I Drink Gatorade - Muscular Dystrophy News - August 23rd, 2017
- PETA report criticizes Yale on treatment of rodents in research - New Haven Register - August 23rd, 2017
- Jerry Lewis Remembered By Younger Fans for Muscular Dystrophy Telethons - NBCNews.com - August 21st, 2017
- The Medical Management of Friedreich's Ataxia - Friedreich's Ataxia News - August 21st, 2017
- Colorado Springs firefighters to kick off 63rd annual Fill the Boot Drive - FOX21News.com - August 19th, 2017
- Stem Cells From Young Hearts Could Rejuvenate Old Hearts - Technology Networks - August 16th, 2017
- Researchers Develop Newborn Screening Tool for Duchenne - Muscular Dystrophy News - August 15th, 2017
- SHEBOYGAN Fire Fighters Support MDA with Annual Fill the Boot Drive - WHBL Sheboygan - August 15th, 2017
- McLinn family champions national 'Right to Try' legislation - Greensburg Daily News - August 12th, 2017
- Mitobridge's Investigational DMD Therapy MA-0211 to Be Tested in Healthy Volunteers in Initial Clinical Trial - Muscular Dystrophy News - August 12th, 2017
- First Charcot-Marie-Tooth Patient Dosed in Phase 2 Clinical Trial of Muscle Impairment Therapy ACE-083 - Muscular Dystrophy News - August 11th, 2017
- New test for screening of Duchenne muscular dystrophy in newborn babies - Medical Xpress - August 11th, 2017
- RNA-targeting CRISPR could yield treatments for Huntington's, ALS - FierceBiotech - August 10th, 2017
- Lives hang in the balance while the FDA bureaucracy churns - Washington Examiner - August 10th, 2017
- Mitobridge's Novel Treatment Approach for Duchenne Muscular ... - Business Wire (press release) - August 8th, 2017
- My Walk with Faith While Living with MD - Muscular Dystrophy News - August 8th, 2017
- Interview - Santhera Readies Muscular Dystrophy Push - Seeking Alpha - August 8th, 2017
- Why were a little girl's muscles as weak as noodles? The answer was unexpected. - Washington Post - August 8th, 2017
- Biotech FibroGen soars more than 50% on positive lung disease treatment study - CNBC - August 8th, 2017
- 'Missing Links' to a Corrective Mechanism for a Severe Muscular Dystrophy - LWW Journals - August 6th, 2017
- Newly Convicted 'Pharma Bro' Martin Shkreli Shined a Light on Pharma's Biggest Scandals - Fortune - August 4th, 2017
- Dogs Are Developing Muscular Dystrophy Because of Cruel Animal Tests Let's End This! - One Green Planet - August 4th, 2017
- Gene Therapy Could Cure Muscular Dystrophy for Dogs and Humans - Edgy Labs (blog) - August 4th, 2017
- Firefighters helping fill the boot for MDA - Plainview Daily Herald - August 4th, 2017
- Children with muscular dystrophy will not get new drug - Irish Times - August 2nd, 2017
- Man's best mend Gene therapy reverses muscular dystrophy symptoms in dogs - Digital Trends - August 2nd, 2017
- Jiffy Lube and MDA Launch 6th Annual MUSCLE UP! Campaign for Kids and Adults Fighting Muscular Dystrophy - PR Newswire (press release) - August 1st, 2017
- U. of Missouri-led scientists improve gene transfer in Duchenne therapy - FierceBiotech - August 1st, 2017
- Muscular Dystrophy News - Muscular Dystrophy News - August 1st, 2017
- FDA Paves Way for Capricor to Hold Phase 2 Trial of CAP-1002 for Duchenne MD - Muscular Dystrophy News - August 1st, 2017
- Myrtle Beach Fire Fighters Support MDA with Annual Fill the Boot Drive - Myhorrynews - August 1st, 2017
- Muscular Dystrophy Reversed in Dogs - Vital Updates - August 1st, 2017
- 7 Myths About Physical Therapy - Muscular Dystrophy News - Muscular Dystrophy News - August 1st, 2017
- Gene therapy reverses muscular dystrophy symptoms in dogs - New Atlas - August 1st, 2017
- One FDA About-Face Doesn't Mean an Orphan-Drug Bonanza - Bloomberg - July 12th, 2017
- Coast-to-Coast Ride Ready For a Big Brooklyn Finish - The Tablet Catholic Newspaper - July 12th, 2017
- FDA Grants Orphan Drug Designation to Mallinckrodt Development Product for Potential Treatment of Duchenne ... - PR Newswire (press release) - July 12th, 2017
- The FDA Approved the First New Sickle Cell Drug in 20 YearsBut It's Not a Cure - Fortune - July 10th, 2017
- Here's Why PTC Therapeutics, Inc. Popped 45.2% in June ... - Madison.com - July 10th, 2017
- Experts Review Current and Potential Treatments for Duchenne Muscular Dystrophy - Muscular Dystrophy News - July 9th, 2017
- Heart Failure Diagnosis and Therapy Reviewed in Duchenne Muscular Dystrophy Patients - Muscular Dystrophy News - July 9th, 2017
- Capricor Regains Rights to CAP-1002 as Janssen Ends Collaboration - Genetic Engineering & Biotechnology News - July 7th, 2017
- Rare-Disease Drugmakers Join in Worries Over GOP Health Overhaul - Bloomberg - July 6th, 2017
- Designed proteins to treat muscular dystrophy - Medical Xpress - Medical Xpress - July 1st, 2017
- Santhera's Raxone Receives First Positive EAMS Scientific ... - GlobeNewswire (press release) - June 25th, 2017
- Potential leukemia drug better aimed at muscular dystrophy, NIH says - Patient Daily - June 25th, 2017
- Altavista community raises money for local firefighter battling form of ... - WSET - June 25th, 2017
- New Analyses of Translarna (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric ... - PR Newswire (press release) - June 22nd, 2017
- Sarepta signs another Duchenne gene therapy pact as it aims for wider treatment - FierceBiotech - June 22nd, 2017
- Researchers Aim to Repurpose Failed Leukemia Drug to Treat ... - Managed Care magazine - June 17th, 2017
- RASRx Receives Orphan Drug Designation from FDA - Business Wire (press release) - June 17th, 2017
- Researchers aim to repurpose former experimental cancer therapy to treat muscular dystrophy - ScienceBlog.com (blog) - June 17th, 2017
- Muscle growth finding may assist with cancer treatment - Medical Xpress - June 14th, 2017
- Researchers aim to repurpose former experimental cancer therapy to treat muscular dystrophy - National Institutes of Health (press release) - June 14th, 2017
- Muscular Dystrophy - KidsHealth - the Web's most visited ... - June 14th, 2017
- Business owner doesn't let muscular dystrophy slow him down - Peoria Journal Star - June 13th, 2017
- PTC Therapeutics Announces FDA Advisory Committee Meeting for ... - PR Newswire (press release) - June 10th, 2017
- 'This is not the way': Bill Maher slams Texas A&M muscular dystrophy doc's 'cruel' dog experiments - Raw Story - June 3rd, 2017
- FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford - Labiotech.eu (blog) - May 31st, 2017
- CD Access to Provide Special Access Program for Duchenne ... - Business Wire (press release) - May 31st, 2017
- AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy - PR Newswire (press release) - May 30th, 2017
- Duchenne Muscular Dystrophy Treatment Market Estimated to ... - MilTech - May 29th, 2017
- Capricor Therapeutics Announces Formation of Duchenne Muscular Dystrophy Advisory Board - PR Newswire (press release) - May 27th, 2017